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Abstract
Prostate cancer is the most frequent noncutaneous cancer occurring in men. On average, men with localized prostate cancer have
a high 10-year survival rate, and many can be cured. However, men with metastatic castrate-resistant prostate cancer have
incurable disease with poor survival despite intensive therapy. This unmet need has led to recent advances in therapy aimed at
treating bonemetastases resulting from prostate cancer. The bonemicroenvironment lends itself tometastases in castrate-resistant
prostate cancer, as a result of complex interactions between the microenvironment and tumor cells. The development of 223ra-
dium dichloride (Ra-223) to treat symptomatic bone metastases has improved survival in men with metastatic castrate-resistant
prostate cancer. Moreover, Ra-223 may have effects on the tumor microenvironment that enhance its activity. Ra-223 treatment
has been shown to prolong survival, and its effects on the immune system are under investigation. Because prostate cancer affects
a sizable portion of the adult male population, understanding how it metastasizes to bone is an important step in advancing
therapy. Clinical trials that are underway should yield new information on whether Ra-223 synergizes effectively with immu-
notherapy agents and whether Ra-223 has enhancing effects on the immune system in patients with prostate cancer.
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1 Introduction
Prostate cancer is the most frequent noncutaneous cancer in
men and is a major health problem in the developed world. It
can be anticipated that with improving life span in developing
countries, prostate cancer will emerge as a major health prob-
lem worldwide. There is a wide range of outcomes based on
the extent of cancer at diagnosis. Overall, men with localized
cancer have a high 10-year survival rate, and many can be
cured. However, men with metastatic prostate cancer have
incurable disease with a poor survival, despite intensive ther-
apy: the 5-year survival rate is only approximately 30%, and
median survival rate is approximately 3 years [1, 2].
Resistance to treatment is one factor accounting for the
poor survival rate. Several mechanisms have been linked to
the emergence of resistance to treatment, including aggressive
variants of prostate cancer, which arise as a result of mutations
in several tumor suppressor genes [3–6]. In addition, androgen
depletion induces genes involved in epithelial-to-
mesenchymal transition, which plays a role in cancer progres-
sion and metastasis [7]. These observations have implicated
the bone–epithelial interaction as a key process in prostate
cancer progression.
The bone microenvironment is the natural subject of re-
search interest, given that bone metastases dominate the clin-
ical picture of advanced prostate cancer and form a major
source of morbidity from the disease [8]. Crosstalk between
tumor cells and osteoblasts, which drives the growth of me-
tastases, is facilitated by soluble factors and by physical con-
tact between the cell types [9, 10]. Investigators hypothesized
that the bidirectional interaction between the epithelium and
host stromal cells in prostate cancer may account for the de-
velopment of resistance and unique patterns of spread. Recent
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experimental results showed that a subset of cancers not ex-
pressing the combined loss profile associated with the p53,
PTEN, or Rb gene was associated with specific gene expres-
sion profiles, including antiapoptotic genes and those promot-
ing tumor spread [11, 12]. Of note, among the genes implicat-
ed in prostate carcinogenesis and resistance to therapy, such as
matrix metalloproteinase (MMP)-11, androgen receptor, and
interleukin (IL)-17 receptor beta, were genes coexpressed by
tumor-associated fibroblasts and tumor cells [11].
In contrast to most approved therapies for prostate cancer,
the life-prolonging, bone-homing radiopharmaceutical 223ra-
dium dichloride (Ra-223) and the therapeutic vaccine
sipuleucel-T exert their therapeutic benefits with only modest
declines in serum prostate-specific antigen (PSA) concentra-
tions [13–15]. Such observations led investigators to speculate
that the life-prolonging effects from these agents in the ab-
sence of proportional declines in PSAwere indirect, the initial
target being both immune and nonimmune tumor-associated
microenvironments. Taken together, these observations have
generated interest in studies linking the mechanism of the
development of bone metastases to the benefits of treatment
with Ra-223.
Recent data show that Ra-223 affects not only tumor cells
but also the bone microenvironment, thereby amplifying the
benefits of treatment with this agent. The goal of this review is
to discuss the current preclinical and clinical literature, includ-
ing experimental systems, prevailing hypotheses, and knowl-
edge gaps that should be applied to the novel pathway-driven
approaches to the treatment of bone metastases in prostate
cancer.
2 The bone microenvironment, tumor
progression, and metastases
in castrate-resistant prostate cancer
Prostate cancer cells home preferentially to osteoblast-rich
regions of the bone [16]. The physical contact between pros-
tate cancer cells and osteoblasts in bone disrupts bone struc-
ture and develops a cycle of mutually enhanced growth by
prostate cancer cells and osteoblasts. In a series of coculture
experiments, Kimura and colleagues demonstrated that osteo-
blasts that were cultured with MDA-PCa-2b cells had in-
creased numbers of both cell types and increased the expres-
sion of alkaline phosphatase [9]. Moreover, in the presence of
prostate cancer cells, osteoblasts did not align along the colla-
gen matrix in a normal fashion, but rather showed a disorga-
nized arrangement that is not reproduced when cells are
cocultured with spent medium from prostate cancer cultures,
indicating a need for direct cell contact [9]. This resulting bone
matrix anisotropy may enhance prostate cancer metastasis [9].
Hypoxia is a major driver of metastases, and the hypoxic
environment of bone induces the expression of hypoxia-
inducible factor (HIF)-1. HIF-1 regulates the expression of
glycolytic enzymes, glucose transporters, and vascular endo-
thelial growth factor (VEGF) [10]. In vitro studies showed that
HIF-1α enhanced the invasive potential of human prostate
cancer cells and increased the expression of MMP-2 and ca-
thepsin D, both of which are involved in cell migration and
invasion [17]. Moreover, hypoxic tissues including neoplasms
are generally less susceptible to energetic X-irradiation.
However, this should not affect the efficacy of Ra-223, be-
cause hypoxia does not modify linear energy transfer in the
range of alpha particles [18].
It is generally accepted that bone metastases in prostate
cancer are an archetypical example of a specific Bseed and
soil^ hypothesis arising from interactions between tumor cells
and the bone microenvironment [19]. This two-compartment
model assumes that interactions occur between the tumor and
the stromal cell compartment (osteoclasts, osteoblasts T cells,
endothelial cells), within bone [20]. Unlike those of many
other solid tumors, the bone metastases of metastatic
castrate-resistant prostate cancer (CRPC) appear phenotypi-
cally osteoblastic rather than osteolytic. Both autocrine and
paracrine factors among the various cell types are involved,
setting up a vicious cycle that drives metastatic growth (Fig. 1)
[21].
Osteoclast stimulatory factors, such as parathyroid
hormone-related protein, transforming growth factor
(TGF)-β, and IL-11, may also be released, stimulating bone
cells and inducing additional factors that promote prostate
cancer growth [10, 22]. On balance, bone metastases favor
bone erosion more than bone formation when resistance to
antiandrogen therapy arises in poorly differentiated or
neuroendocrine-type tumors. In a series of experiments,
Ottewell and colleagues showed that castrated mice had en-
hanced bone resorption and subsequent loss of bone volume
compared with sham-operated mice. Moreover, castration
triggered growth of prostate cancer cells to form bone metas-
tases in 70% of mice, whereas few sham-operated mice had
observable bone metastases. By 2 weeks following castration,
osteoclast numbers were increased in castrated mice but not in
sham-operated mice [8].
Once established, bone metastases enter an autocatalytic
vicious cycle of enhancing growth and progression of prostate
cancer even as bone metastases develop and grow (Fig. 1).
Tumor-derived factors, such asMMPs, chemokine receptor-4,
vascular endothelial growth factor (VEGF), and connective
tissue growth factor, target metastatic prostate cancer cells to
bone and facilitate their survival within it. Physical factors
within bone, such as hypoxia, low pH, and extracellular
Ca2+, activate signaling pathways within prostate cancer cells,
leading to the additional release of factors (e.g., TGF-β and
insulin-derived growth factors), which, in animal models, en-
hance survival and growth within bone [10]. Moreover, these
factors activate the expression of osteoblast stimulatory
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factors by prostate cancer cells, including VEGF, platelet-
derived growth factor, bone morphogenic protein-2, insulin-
like growth factor-1, and endothelin-1 [23–25].
3 Patient-derived xenografts and other
models to study metastasis formation
and guide treatment
Biological models helped elucidate mechanisms underlying
cancer progression and resistance to therapy and contributed
significantly to modern treatment of many adult solid tumors.
Successful approaches have largely focused on genetically
engineered mouse models and cell lines suitable for in vivo
studies. However, the usefulness of these models is restricted
to cancers whose growth is driven primarily by cancer cells,
without significant contribution from the tumor-associatedmi-
croenvironment (TME), and furthermore, by the lack of sim-
ilarity to lesions seen in the clinic: osteoclastic rather than the
sclerotic lesions seen in patients.
Prostate cancer differs from many adult solid tumors in its
marked dependence on the TME. This dependence has made
it difficult to develop models reflective of human prostate
cancer. Moreover, prostate cancer cell lines are driven by au-
tocrine growth factors in cell lines such as DU-145, which are
mostly grown in the absence of TMEs [26]. Therefore, better
model systems are needed that more accurately mimic the
complex interaction between prostate cancer cells and the
TME [27].
Patient-derived xenografts (PDX) address the complex in-
teraction between prostate cancer cells and the TME because
they include the TME host component. The potential of these
models to discover targets or establish proof of principle ad-
vanced most knowledge in human–murine coclinical studies.
This approach of integrating human and mouse studies has
proven more informative than using single-species studies ex-
clusively. These integrated research strategies have led to the
identification of potential new targets for the treatment of bone
metastases in prostate cancer [28].
A study using the PDX model MDA PCa-118b implicated
fibroblast growth factor (FGF)-9 in the pathogenesis of bone
metastases in prostate cancer; PDXmice treated with antibody
to FGF-9 developed smaller tumors within bone and reduced
ectopic bone formation compared with control mice [29].
Another study demonstrated the role of FGF in establishing
bone metastases and the potential therapeutic value of treating
bone metastases in prostate cancer with the FGF inhibitors
dovitinib and cabozantinib, although phase 3 studies indicated
that the potential will not be met with cabozantinib, at least in
the population tested [23, 28, 30, 31].
Moreover, using prostate cancer PDX, investigators recent-
ly reported that FGF receptor 1 may be a mechanism of ac-
quired resistance to cabozantinib. Cabozantinib inhibits
VEGF and c-MET, in addition to FGF, and in prostate cancer
studies, was shown to activate innate immunity [32]. Studies
Fig. 1 Matrix metalloproteinases (MMPs), chemokine receptor (CXCR)-
4, vascular endothelial growth factor (VEGF), and connective tissue
growth factor (CTGF) target metastatic tumor cells to bone and
facilitate their survival within the bone microenvironment. Physical
factors within bone, including hypoxia, acidic pH, and extracellular
Ca2+, and bone-derived growth factors, such as tumor growth factor
(TGF)-β and insulin-like growth factors (IGFs), activate tumor
expression of osteoblast-stimulatory factors, such as VEGF, platelet-
derived growth factor (PDGF), and endothelin-1 (ET-1). Osteoclast-
stimulatory factors can also be increased, which in turn release factors
that promote tumor growth in bone. Republished with permission of the
American Association of Cancer Research, from [10]. Permission
conveyed through Copyright Clearance Center, Inc.
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using PDX showed that cabozantinib did not inhibit prostate
cancer cells, but instead, inhibited VEGF receptor 2 and c-Met
expressed by endothelial cells. In addition, direct effects of
cabozantinib on osteoblasts accounted for tumor inhibition,
which was seen in the PDX model and in a phase 2 trial, in
which 16 of the 20 enrolled patients showed ≥ 30% reduction
in bone scan lesion area (the marker for tumor response) [28].
As mentioned previously, final analysis of the phase 3 studies
showed that cabozantinib improved bone scan response and
progression-free survival, without significantly increasing
overall survival (OS) or improving pain response [30, 31].
A major theoretical advantage of using PDXmodels is that
they are frequently established while donors are alive, and
therefore can be linked prospectively with clinical disease
progression [33]. In a pilot study of patients with advanced
solid tumors, PDX-guided treatment resulted in 11 partial re-
sponses among 14 patients, with an objective response rate of
88% [34].
However, in practice, PDX models, though highly infor-
mative, have proven too cumbersome to be widely applicable
guides to individualized therapy. Among the other disadvan-
tages of PDX models are their inability to account for the
immune microenvironment and their slow rate of growth.
These limitations have led investigators to adopt a panel of
models that span in vitro and in vivo system and annotated
clinical tissue that need to be subjected to integrated analyses.
Other models have been used to elucidate specific aspects
of metastatic CRPC. For example, a trabecular bone model
was used to examine the effects of alpha-emitting therapy,
such as Ra-223 on bone marrow. Such a model comprises a
sphere of tissue having a shell that is composed of bone (os-
teoblasts and other cells) surrounding a trabecular cavity that
contains marrow cells. Hobbs and colleagues predicted that
increased bone marrow toxicity should not result from the use
of Ra-223 to treat bone metastases of CRPC, although they
noted that the deposition of daughter nuclides in bone could
not be accurately assessed by the model [35].
4 Preclinical data demonstrating Ra-223
efficacy for treating bone metastases
in castrate-resistant prostate cancer
Since its discovery by the Curies, radium has been known to
damage tissue and, therefore, could be used for cancer therapy.
An alkaline earth element, radium behaves similarly to calci-
um and combines with hydroxyapatite in bone. Ra-223 emits
primarily alpha particles, which are particles with poor tissue
penetration that can be shielded by a sheet of paper [36].
Preclinical studies in mice showed that the parenteral admin-
istration of Ra-223 resulted in its accumulation predominantly
in bone tissue (femurae and skull) and preferentially at sites of
increased osteoblastic activity, with some deposition in soft
tissues (large and small intestines and spleen). Studies also
showed that measurable daughter nuclides (e.g., Bi-211) were
likewise retained in bone, although some migration to soft
tissue was noted (< 2%) [37]. These results implied that the
majority of the energy from Ra-223 decay could be expected
to remain within bone tissue and immediately adjacent to the
bone surface.
Because overexpression of growth factors, such as epider-
mal growth factor, confers some radioresistance to cancer
lines, a series of mouse xenograft studies were performed to
determine the extent of prostate cancer cell sensitivity to al-
pha-particle, beta-particle, or gamma-particle emitters. The
findings were as expected: both androgen-sensitive and
androgen-resistant prostate cancer cells responded nearly
equally to irradiation by Ra-223, Lu-177 (beta-particle emit-
ter), or Cs-137 (gamma-particle emitter), providing the ratio-
nale for using such emitters in the clinic for all disease states
[38].
Other studies in tumor-bearing mice showed that the ma-
jority of the Ra-223 accumulation occurred in bone, with
some deposition in kidneys, intestines, and spleen. Within
bone, most of the Ra-223 deposition occurred at sites of in-
creased osteoblastic activity. Ra-223 did not accumulate with-
in tumor cells but rather along the apposite bone surfaces [39].
In prostate cancer xenograft models using LNCaP
(androgen-sensitive) and LuCaP 58 (abiraterone-resistant) cell
lines, Ra-223 showed inhibitory effects on experimental bone
metastases, while preserving bone structure [14]. Intratibial
injection of either cell line in mice set up tumors mimicking
bone metastases. Mice were given Ra-223 based on serum
PSA levels, and analyses were performed to determine the
effect of treatment on several bone and tumor parameters.
Ra-223 reduced osteoblastic bone growth, while preserving
bone architecture and bone volume. Moreover, Ra-223
lowered serum PSA levels and reduced tumor volumes and
markers of bone metabolism. Double-stranded DNA breaks
were also detected in osteoblasts and osteoclasts within tumor
lesions. These results indicate a dual mechanism of action of
Ra-223 for inhibiting both tumor growth and pathological
new bone formation adjacent to tumor foci [14].
5Direct and indirect effects of Ra-223 on bone
metastases in castrate-resistant prostate
cancer
Radiation has long been a mainstay treatment for bone metas-
tases. External-beam radiation therapy (EBRT) provides pain
relief, but can damage healthy tissue and tumor tissue. Bone-
seeking radiopharmaceuticals, such as Ra-223 or strontium
(Sr)-89, were developed to treat multiple lesions with systemic
therapy, and thus complement EBRT. Both Ra and Sr are
elements that displace Ca in mineralized bone. Sr-89 is a beta
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emitter, whereas Ra-223, as noted previously, is an alpha emit-
ter. [40] These radiopharmaceuticals cause li t t le
myelosuppression. The beta particles emitted by Sr-89 have
longer path lengths (100 mm) than the alpha particles of Ra-
223 (< 100 μm), which means that the energy of Sr-89 may
exert more collateral damage to bone marrow than would Ra-
223 [37].
Because alpha particles are helium nuclei and thus relative-
ly heavy charged particles, alpha emitters, such as Ra-223,
deliver high-linear energy transfer radiation into cells within
the short path length, resulting in nonreparable double-
stranded DNA breaks. The sum of these types of damage
may limit the regrowth of dormant tumor cells within bone.
Additional advantages of alpha particles include no need for
elaborate shielding, and the relatively short half-life (11.4 days)
of Ra-223 specifically means that waste disposal poses fewer
challenges than would be the case with long-lived nuclides.
Moreover, compared with beta-emitting nuclides, particles
produced by alpha-emitting nuclides are more energetic and
have high-linear energy transfer. Alpha particles cause pre-
dominantly nonreparable double-stranded breaks in DNA
and, thus, are more toxic to tissue than beta particles [40].
Clinical data show that Ra-223 contributes to an increase in
survival expectations, in addition to its effects on bone metas-
tases in CRPC [13]. Results of the ALSYMPCA (ALpharadin
in SYMPtomatic Prostate Cancer; NCT00699751) trial
showed that Ra-223 improved OS in patients with CRPC,
irrespective of previous treatment with docetaxel chemother-
apy [15, 41]. Treatment with Ra-223 significantly increased
the median OS to 14.9 months compared with 11.3 months for
placebo (P < .001) and reduced the risk for death by 30%
among patients who received standard of care (Fig. 2) [15].
When patients were stratified based on whether they previous-
ly received docetaxel, Ra-223 prolonged the median OS for
both subgroups (hazard ratio [HR], 0.70 for patients who had
previous docetaxel use; P = .002; HR, 0.69 for patients who
had no previous docetaxel use, P = .01) [41]. In both studies,
Ra-223 was well tolerated [15, 41].
Having established the efficacy of Ra-223 as an effective
single agent in advanced, late-stage CRPC, current trials focus
on the earlier use of Ra-223 alongside other agents, such as
ab i r a t e rone (NCT02043678) and enza lu t amide
(NCT02199197). Data from an expanded access program that
included patients with metastatic CRPC receiving a variety of
treatments showed that Ra-223 could be combined with
enzalutamide or abiraterone, even if patients are symptomatic,
and that Ra-223 combined with antiandrogen receptor therapy
modulates the bone microenvironment [42, 43]. The results of
the ongoing clinical trials should reveal the effects of the com-
bination treatment on prolonged survival.
Radium therapy likely has effects beyond direct effects on
tumor cells; Ra-223 treatment may modulate immune re-
sponses similar to adjuvant therapy or modify the tumor mi-
croenvironment in such a manner as to allow more effective T
cell ingress. In some studies, subtherapeutic doses of Ra-223
enhanced cell killing by T cells and expression of major his-
tocompatibility markers on antigen-presenting cells (indirect-
ly enhancing T cell activity) [44, 45]. Moreover, memory
cells, but not naïve T cells, were found to be radioresistant,
an observation that could be exploited in combining immuno-
therapy with Ra-223 treatment [44].
Even more important in today’s treatment landscape is the
observed interaction between radiotherapy and the checkpoint
inhibitor anti-programmed cell death ligand 1 (anti-PD-L1)
Fig. 2 Kaplan–Meier estimates of
overall survival (OS) show that
treatment with Ra-223 increased
the median OS significantly
relative to placebo, from 11.3 to
14.9 months (P < .001; hazard
ratio, 0.70; 95% confidence
interval, 0.58–0.83). Republished
with permission of [15].
Permission conveyed through
Copyright Clearance Center, Inc.
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antibody in animal models. In preclinical studies, researchers
showed that PD-L1 expression was increased following expo-
sure to ionizing radiation and that the administration of anti-
PD-L1 antibody synergized with radiation treatment to reduce
suppressor cells localized to the tumor environment. This, in
turn, enhanced antitumor cytotoxic T cell function as a direct
result of this synergy [46].
6 Unanswered questions and future
directions
Ra-223 has been shown to prolong survival and improve
symptoms in men with metastatic CRPC who have symp-
tomatic bone metastases. These benefits have been asso-
ciated with a consistent decline in serum alkaline phos-
phatase levels, without a proportional decline in serum
PSA levels or limiting myelosuppression. The high-
linear energy transfer of alpha particles emitted by Ra-
223 causes localized tissue destruction [47]. This low lev-
el of myelosuppression allows Ra-223 to be combined
with chemotherapy having some level of bone marrow
toxicity [47]. In addition, Ra-223 should accumulate pref-
erentially where there is osteoblastic growth surrounding
osteolytic lesions and therefore deliver its therapeutic ef-
fects in targeted anatomical regions [47].
Perhaps, the most promising is the potential for combina-
tions of bone-targeted therapies to prevent progression as op-
posed to solely treating existingmetastases. Exploring rational
combinations of approved agents (i.e., second-generation
antiandrogen drugs) or agents in development is a high-
priority area of study that builds on the progress made to date.
One trial, ERA-223, explores the value of adding Ra-223 to
abiraterone (plus pedisone or prednisolone; NCT02043678).
Patient accrual has completed (806 enrolled), and results are
expected in the next 2 years.
One future direction with Ra-223 therapy may be to
combine it with immunotherapy. One trial that is under-
way (NCT03093428) will determine whether the combi-
nation of Ra-223 and pembrolizumab (US Food and Drug
Administration [FDA]-approved anti-PD-L1 antibody) has
shown early promise in patients with metastatic CRPC. In
this trial, patients who previously received enzalutamide
or abiraterone will receive Ra-223 plus pembrolizumab
either concurrently or on a staggered regimen. The prima-
ry end point is the extent of immune-cell (e.g., CD8+ and
CD4+ T cells) infiltration in bone biopsy specimens from
baseline to 8 weeks following the start of study treatment.
The secondary end points include safety, tolerability, and
tumor e f f i cacy me t r i c s . Ano the r c l in i ca l t r i a l
(NCT02814669) will evaluate the safety and tolerability
of atezolizumab plus Ra-223 in metastatic CRPC follow-
ing treatment with an androgen pathway inhibitor.
Atezolizumab, like pembrolizumab, is an FDA-approved
anti-PD-L1 antibody.
As factors involved in bone metastases are identified
and novel agents targeted to these factors are recognized,
new trials are anticipated to test combinations of new
agents with Ra-223 in CRPC. One pathway that could
yield new agents is the TBX2-WNT signaling axis.
TBX2 is a transcription factor that is overexpressed in
bone metastases of CRPC, which acts through the WNT
signaling pathway shown to be involved in prostate can-
cer progression and bone metastases. Blocking TBX2 re-
duced bone metastases and tumor growth in mouse pros-
tate cancer xenograft models [48].
7 Conclusion
Bone metastases in CRPC arise from complex interactions
among factors that drive prostate cancer progression and
lead to more bone metastases. Among the treatments for
bone metastases, Ra-223 has unique properties that en-
hance not only its capability to inhibit bone metastases,
but also its ability to influence the bone microenviron-
ment in ways that may augment antitumor activities with-
in the body and thereby prolong OS. Results of ongoing
and future trials will help determine optimal treatment
combinations and sequencing of effective therapies to pre-
vent and treat bone metastases in CRPC.
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